Innovations and Challenges in Renal Cancer

Innovations and Challenges in Renal Cancer, chaired by Michael B. Atkins, was held March 19 to 20, 2004, in Cambridge, MA. The conference brought together leading experts in the fields of cancer research, medical oncology, urology, and radiology who wished to exchange information and perspectives

[1]  W. Marston Linehan,et al.  Genetic Basis of Cancer of the Kidney , 2004, Clinical Cancer Research.

[2]  W. Kaelin.  The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer , 2004, Clinical Cancer Research.

[3]  O. Iliopoulos,et al.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. , 2004, Molecular cancer research : MCR.

[4]  W. Kaelin,et al.  Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.

[5]  S. Richard,et al.  Inactivation of BHD in sporadic renal tumors. , 2003, Cancer research.

[6]  Tsutomu Ohta,et al.  Overexpression of KIT in chromophobe renal cell carcinoma , 2003, Oncogene.

[7]  Maria Merino,et al.  Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. , 2002, Cancer cell.

[8]  P. Choyke,et al.  Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  G. Nikiforidis,et al.  Adenocarcinoma of the kidney: Nephron‐sparing surgical approach vs. radical nephrectomy , 1999, Journal of surgical oncology.

[10]  S. Saga,et al.  MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas , 1999, British Journal of Cancer.

[11]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[13]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[14]  B. Barlogie,et al.  Graft-versus-myeloma effect: proof of principle. , 1996, Blood.

[15]  P. Choyke,et al.  Hereditary papillary renal cell carcinoma. , 1994, The Journal of urology.

[16]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[17]  P. Choyke,et al.  Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. , 1990, Genomics.

[18]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[19]  H. Muss,et al.  Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Dekernion,et al.  Prognostic factors in metastatic renal carcinoma. , 1986, The Journal of urology.